Undoubtedly, we could confidently say that reducing Lp(a) levels is crucial in controlling and reducing the severity of CAD in these patients, however without improving the other cardiometabolic biomarker, the reduction of raised Lp(a) levels may be a little misleading. The gene discussed is LPA; the disease is coronary artery disorder.